Medical Equipment

Cancer Biomarker Market Projected To Reach $52.63 Billion By 2030 At 16% CAGR

April 10, 2026April 10, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Cancer Biomarker Market In 2026, And How Will Its Value Evolve By 2030?

The cancer biomarker market has shown rapid expansion in recent years. It is projected to increase from $25.09 billion in 2025 to $29.07 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.9%. The drivers for this growth in prior periods include increasing cancer prevalence worldwide, advancements in molecular biology research, expansion of oncology research funding, rising adoption of biomarker-based diagnostics, and improvements in imaging and assay technologies.

The cancer biomarker market size is projected to experience substantial expansion in the coming years, reaching a value of $52.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.0%. This anticipated growth during the forecast period is primarily driven by an escalating need for individualized oncology treatments, heightened investments in precision medicine, the ongoing development of biomarker-driven drugs, the expanding application of AI-based biomarker analysis, and an increased emphasis on detecting cancer in its early stages. Key developments expected within this period encompass the greater utilization of genetic and protein biomarkers, a surge in the adoption of companion diagnostics, the broader incorporation of omics technologies, the widening scope of liquid biopsy applications, and a reinforced commitment to identifying cancer early.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Drivers Are Supporting The Cancer Biomarker Market Growth?

The increasing occurrence of cancer is a primary catalyst for the expansion of the cancer biomarker market. Cancer incidence rate refers to the count of new cancer cases of a particular type or site observed within a specific population over a year, expressed as cancers per 100,000 individuals at risk. This escalating incidence of cancer is driving the widespread application of cancer biomarkers, as they are instrumental in assessing disease risk, screening for occult primary tumors, differentiating benign from malignant indicators, or distinguishing between various forms of malignancy. Cancer biomarkers aid in the early identification, diagnosis, and ongoing surveillance of cancer by signaling the disease’s presence or progression, which enables customized treatment plans and improves patient outcomes. For instance, in May 2024, a report released by the International Agency for Research on Cancer (IARC), a France-based cancer research organization, stated that in 2022, approximately 20 million new cancer cases were reported, leading to 9.7 million deaths. Furthermore, by 2050, it is projected that new cancer cases will surpass 35 million, signifying a 77% increase compared to 2022. Thus, the escalating incidence of cancer is expected to vigorously propel the growth of the cancer biomarker market in the upcoming years.

What Are The Main Segments Within The Cancer Biomarker Market Segment Structure?

The cancer biomarker market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types

2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers

Which Trends Are Expected To Impact The Cancer Biomarker Market?

Leading companies within the cancer biomarker market are concentrating on developing advanced solutions, such as AI-driven cancer biomarkers, with the goal of improving diagnostic precision and personalizing treatment approaches for patients. AI-powered cancer biomarkers represent biological indicators of cancer that are identified and analyzed through artificial intelligence technologies. For example, in September 2023, Ibex Medical Analytics, a US-based entity, introduced Galen Breast HER2, an AI-enhanced solution crafted to boost the accuracy and consistency of HER2 scoring in individuals with breast cancer. This innovative platform assists pathologists by automatically detecting invasive tumor regions and quantifying HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system leverages a novel computational framework to examine immunohistochemistry (IHC)-stained slides, delivering detailed visual insights into staining patterns and enabling pathologists to make well-informed treatment decisions.

Who Are The Companies Participating In The Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Get The Full Cancer Biomarker Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Region Is The Leading Market For The Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Biomarker Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

Browse Through More Reports Similar to the Global Cancer Biomarker Market 2026, By The Business Research Company

Calcium Peroxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-peroxide-global-market-report

Calcium Channel Blocker Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Calcium Nitrate Market Report 2026

https://www.thebusinessresearchcompany.com/report/calcium-nitrate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795